A Phase Ib/II Trial of Trastuzumab-DM1 with Pertuzumab for Patients with HER2-Positive, Locally Advanced or Metastatic Breast Cancer: Interim Efficacy and Safety Results

被引：1
|
作者：
Dieras, V.
Harbeck, N.
Albain, K.
Burris, H.
Awada, A.
Crivellari, D.
Andre, F.
Choi, Y. J.
Huang, J.
Miller, K. D.
机构：
[1] Inst Curie, Paris, France
[2] Univ Cologne, Cologne, Germany
[3] Loyola Univ, Maywood, IL 60153 USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Inst Jules Bordet, B-1000 Brussels, Belgium
[6] Ctr Riferimento Oncol, Aviano, Italy
[7] Inst Gustave Roussy, Villejuif, France
[8] Genentech Inc, San Francisco, CA 94080 USA
[9] IU Simon Canc Ctr, Indianapolis, IN USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P3-14-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-14-01
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Responses to Subsequent Anti-HER2 Therapy after Treatment with Trastuzumab-DM1 in Women with HER2-Positive Metastatic Breast Cancer
    Olson, E. M.
    Lin, N. U.
    DiPiro, P. J.
    Najita, J.
    Krop, I. E.
    Winer, E. P.
    Burstein, H. J.
    CANCER RESEARCH, 2010, 70
  • [42] Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial
    Wang, Zijing
    Liu, Jiaxuan
    Ma, Fei
    Wang, Jiayu
    Luo, Yang
    Fan, Ying
    Yuan, Peng
    Zhang, Pin
    Li, Qing
    Li, Qiao
    Xu, Binghe
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 188 (02) : 441 - 447
  • [43] Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial
    Zijing Wang
    Jiaxuan Liu
    Fei Ma
    Jiayu Wang
    Yang Luo
    Ying Fan
    Peng Yuan
    Pin Zhang
    Qing Li
    Qiao Li
    Binghe Xu
    Breast Cancer Research and Treatment, 2021, 188 : 441 - 447
  • [44] Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival
    Maly, Joseph J.
    Macrae, Erin R.
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2014, 8 : 81 - 88
  • [45] Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer
    Kalinsky, Kevin
    Chi, Dow-Chung
    Lee, Shing Mirn
    Adelson, Kerin B.
    Crew, Katherine D.
    Chuang, Ellen
    Makower, Della
    Hershman, Dawn L.
    Califano, Andrea
    Silva, Jose
    Maurer, Matthew A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [46] The efficacy of trastuzumab, pertuzumab, and docetaxel in patients with HER-2-positive metastatic breast cancer
    Liem, Jean A.
    Kurniawan, Andree
    Christiano, Joysya
    Argo, Teresa M.
    Law, Natasha K.
    Asafia, Darlene
    ANNALS OF ONCOLOGY, 2022, 33 : S538 - S538
  • [47] Phase I/II Trial of Ibrutinib Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer
    O'Shaughnessy, Joyce
    Glidden, Andrea
    Locke, Tracy
    Scales, Amy
    CANCER RESEARCH, 2024, 84 (09)
  • [48] Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
    Lu, Dan
    Burris, Howard A., III
    Wang, Bei
    Dees, E. Claire
    Cortes, Javier
    Joshi, Amita
    Gupta, Manish
    Yi, Joo-Hee
    Chu, Yu-Waye
    Shih, Ted
    Fang, Liang
    Girish, Sandhya
    CURRENT DRUG METABOLISM, 2012, 13 (07) : 911 - 922
  • [49] Pertuzumab, trastuzumab, and docetaxel for HER2-positive early or locally advanced breast cancer in the neoadjuvant setting: Efficacy and safety analysis of a randomized phase III study in Asian patients (PEONY)
    Shao, Z.
    Pang, D.
    Yang, H.
    Li, W.
    Wang, S.
    Cui, S.
    Liao, N.
    Wang, Y.
    Wang, C.
    Chang, Y-C
    Wang, H.
    Kang, S. Y.
    Jiang, Z.
    Li, J.
    Zhou, J.
    Althaus, B.
    Mao, Y.
    Eng-Wong, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [50] Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer
    Olson, E. M.
    Lin, N. U.
    DiPiro, P. J.
    Najita, J. S.
    Krop, I. E.
    Winer, E. P.
    Burstein, H. J.
    ANNALS OF ONCOLOGY, 2012, 23 (01) : 93 - 97
12345